// App-Quantinova.ai

2565 : Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Researchers

Presenter

  • Tanya Siddiqi

Principal Investigators

  • Ulrich Jaeger

  • Olga Moshkovich

  • Jennifer Devlen

  • Matthew Miera

  • Agnes Williams

  • Jens Hasskarl

  • Fei Fei Liu

  • Julia Braverman

  • Gilles Salles

Medical Centers

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

  • ICON PLC, Gaithersburg, MD

  • NCRI, London, United Kingdom

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Bristol-Myers Sqiubb, Princeton, NJ

  • GINECO & Centre Hospitalier Lyon-Sud, Lyon, France

Locations

  • United States

  • Austria

  • United Kingdom

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Lisocabtagene maraleucel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved